S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in
CVE:MDP

Medexus Pharmaceuticals Competitors

C$6.80
-0.22 (-3.13 %)
(As of 03/5/2021 03:59 PM ET)
Add
Compare
Today's Range
C$6.55
Now: C$6.80
C$7.38
50-Day Range
C$6.96
MA: C$7.99
C$9.70
52-Week Range
C$1.42
Now: C$6.80
C$9.75
Volume91,729 shs
Average Volume90,818 shs
Market CapitalizationC$129.82 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Medexus Pharmaceuticals (CVE:MDP) Vs. EPI, WMD, NINE, ASP, FLWR, and RX

Should you be buying MDP stock or one of its competitors? Companies in the industry of "drug manufacturers - specialty & generic" are considered alternatives and competitors to Medexus Pharmaceuticals, including ESSA Pharma (EPI), WeedMD (WMD), Delta 9 Cannabis (NINE), Acerus Pharmaceuticals (ASP), The Flowr (FLWR), and BioSyent Inc. (RX.V) (RX).

Medexus Pharmaceuticals (CVE:MDP) and ESSA Pharma (CVE:EPI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings and valuation.

Earnings & Valuation

This table compares Medexus Pharmaceuticals and ESSA Pharma's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medexus PharmaceuticalsC$108.29 million1.20C$-34,573,801.00C($1.81)-3.75
ESSA PharmaN/AN/AN/AC($0.99)-8.27

ESSA Pharma has lower revenue, but higher earnings than Medexus Pharmaceuticals. ESSA Pharma is trading at a lower price-to-earnings ratio than Medexus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medexus Pharmaceuticals and ESSA Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medexus PharmaceuticalsN/AN/AN/A
ESSA PharmaN/AN/AN/A

Analyst Ratings

This is a summary of recent recommendations and price targets for Medexus Pharmaceuticals and ESSA Pharma, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medexus Pharmaceuticals00203.00
ESSA Pharma0000N/A

Medexus Pharmaceuticals presently has a consensus price target of C$5.00, suggesting a potential downside of 26.47%. Given Medexus Pharmaceuticals' higher possible upside, research analysts plainly believe Medexus Pharmaceuticals is more favorable than ESSA Pharma.

Summary

Medexus Pharmaceuticals beats ESSA Pharma on 4 of the 5 factors compared between the two stocks.

Medexus Pharmaceuticals (CVE:MDP) and WeedMD (CVE:WMD) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.

Earnings and Valuation

This table compares Medexus Pharmaceuticals and WeedMD's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medexus PharmaceuticalsC$108.29 million1.20C$-34,573,801.00C($1.81)-3.75
WeedMDC$27.21 million3.25C$-18,540,456.00C($0.09)-4.77

WeedMD has lower revenue, but higher earnings than Medexus Pharmaceuticals. WeedMD is trading at a lower price-to-earnings ratio than Medexus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Medexus Pharmaceuticals and WeedMD's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medexus PharmaceuticalsN/AN/AN/A
WeedMDN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Medexus Pharmaceuticals and WeedMD, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medexus Pharmaceuticals00203.00
WeedMD01002.00

Medexus Pharmaceuticals presently has a consensus price target of C$5.00, suggesting a potential downside of 26.47%. WeedMD has a consensus price target of C$0.58, suggesting a potential upside of 36.90%. Given WeedMD's higher possible upside, analysts clearly believe WeedMD is more favorable than Medexus Pharmaceuticals.

Medexus Pharmaceuticals (CVE:MDP) and Delta 9 Cannabis (CVE:NINE) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, risk, valuation, dividends, earnings, profitability and institutional ownership.

Profitability

This table compares Medexus Pharmaceuticals and Delta 9 Cannabis' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medexus PharmaceuticalsN/AN/AN/A
Delta 9 CannabisN/AN/AN/A

Analyst Recommendations

This is a breakdown of recent ratings and target prices for Medexus Pharmaceuticals and Delta 9 Cannabis, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medexus Pharmaceuticals00203.00
Delta 9 Cannabis0000N/A

Medexus Pharmaceuticals presently has a consensus price target of C$5.00, suggesting a potential downside of 26.47%. Given Medexus Pharmaceuticals' higher possible upside, equities analysts clearly believe Medexus Pharmaceuticals is more favorable than Delta 9 Cannabis.

Earnings and Valuation

This table compares Medexus Pharmaceuticals and Delta 9 Cannabis' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medexus PharmaceuticalsC$108.29 million1.20C$-34,573,801.00C($1.81)-3.75
Delta 9 CannabisC$12.87 million6.94C$4.69 millionC$0.0519.07

Delta 9 Cannabis has lower revenue, but higher earnings than Medexus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Delta 9 Cannabis, indicating that it is currently the more affordable of the two stocks.

Summary

Delta 9 Cannabis beats Medexus Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Acerus Pharmaceuticals (TSE:ASP) and Medexus Pharmaceuticals (CVE:MDP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.

Profitability

This table compares Acerus Pharmaceuticals and Medexus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Acerus PharmaceuticalsN/AN/AN/A
Medexus PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for Acerus Pharmaceuticals and Medexus Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Acerus Pharmaceuticals0000N/A
Medexus Pharmaceuticals00203.00

Medexus Pharmaceuticals has a consensus target price of C$5.00, suggesting a potential downside of 26.47%. Given Medexus Pharmaceuticals' higher possible upside, analysts clearly believe Medexus Pharmaceuticals is more favorable than Acerus Pharmaceuticals.

Earnings & Valuation

This table compares Acerus Pharmaceuticals and Medexus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Acerus PharmaceuticalsC$1.33 million57.89C$-44,590,052.00C($0.03)-1.72
Medexus PharmaceuticalsC$108.29 million1.20C$-34,573,801.00C($1.81)-3.75

Medexus Pharmaceuticals has higher revenue and earnings than Acerus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than Acerus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Summary

Medexus Pharmaceuticals beats Acerus Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

The Flowr (CVE:FLWR) and Medexus Pharmaceuticals (CVE:MDP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.

Profitability

This table compares The Flowr and Medexus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
The FlowrN/AN/AN/A
Medexus PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for The Flowr and Medexus Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
The Flowr0000N/A
Medexus Pharmaceuticals00203.00

The Flowr presently has a consensus target price of C$0.70, suggesting a potential upside of 125.81%. Medexus Pharmaceuticals has a consensus target price of C$5.00, suggesting a potential downside of 26.47%. Given The Flowr's higher possible upside, research analysts clearly believe The Flowr is more favorable than Medexus Pharmaceuticals.

Earnings & Valuation

This table compares The Flowr and Medexus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
The FlowrC$5.96 million17.13C$-128,870,081.00C($0.39)-0.79
Medexus PharmaceuticalsC$108.29 million1.20C$-34,573,801.00C($1.81)-3.75

Medexus Pharmaceuticals has higher revenue and earnings than The Flowr. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than The Flowr, indicating that it is currently the more affordable of the two stocks.

Summary

The Flowr beats Medexus Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

BioSyent Inc. (RX.V) (CVE:RX) and Medexus Pharmaceuticals (CVE:MDP) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, earnings, dividends, profitability, risk and institutional ownership.

Profitability

This table compares BioSyent Inc. (RX.V) and Medexus Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
BioSyent Inc. (RX.V)N/AN/AN/A
Medexus PharmaceuticalsN/AN/AN/A

Earnings & Valuation

This table compares BioSyent Inc. (RX.V) and Medexus Pharmaceuticals' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioSyent Inc. (RX.V)C$22.18 million4.22C$4.10 millionC$0.3222.81
Medexus PharmaceuticalsC$108.29 million1.20C$-34,573,801.00C($1.81)-3.75

BioSyent Inc. (RX.V) has higher earnings, but lower revenue than Medexus Pharmaceuticals. Medexus Pharmaceuticals is trading at a lower price-to-earnings ratio than BioSyent Inc. (RX.V), indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and recommmendations for BioSyent Inc. (RX.V) and Medexus Pharmaceuticals, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
BioSyent Inc. (RX.V)02002.00
Medexus Pharmaceuticals00203.00

BioSyent Inc. (RX.V) presently has a consensus target price of C$7.00, suggesting a potential downside of 4.11%. Medexus Pharmaceuticals has a consensus target price of C$5.00, suggesting a potential downside of 26.47%. Given BioSyent Inc. (RX.V)'s higher possible upside, research analysts clearly believe BioSyent Inc. (RX.V) is more favorable than Medexus Pharmaceuticals.

Summary

BioSyent Inc. (RX.V) beats Medexus Pharmaceuticals on 5 of the 8 factors compared between the two stocks.


Medexus Pharmaceuticals Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
EPI
ESSA Pharma
0.6$8.20-6.7%C$145.78 millionN/A-8.27
WMD
WeedMD
1.3$0.42-2.4%C$95.35 millionC$27.21 million-4.77
NINE
Delta 9 Cannabis
0.8$1.03-2.9%C$89.36 millionC$12.87 million19.07Gap Down
Acerus Pharmaceuticals logo
ASP
Acerus Pharmaceuticals
0.5$0.05-0.0%C$76.88 millionC$1.33 million-1.72Upcoming Earnings
News Coverage
FLWR
The Flowr
1.0$0.31-9.7%C$70.01 millionC$5.96 million-0.79
RX
BioSyent Inc. (RX.V)
1.0$7.30-2.7%C$64.81 millionC$22.18 million22.81
IN
InMed Pharmaceuticals Inc. (IN.TO)
0.6$5.50-2.5%C$44.28 millionN/A-3.81Gap Up
VIR
Viridium Pacific Group
0.7$0.38-5.3%C$37.54 millionC$1.09 million-2.97Gap Down
ZOM
Zomedica Pharmaceuticals Corp. (ZOM.V)
0.6$0.29-7.0%C$36.73 millionN/A-2.61Gap Up
NDVA
Indiva
1.1$0.51-2.0%C$27.54 millionC$7.92 million-3.98News Coverage
Cipher Pharmaceuticals Inc. (CPH.TO) logo
CPH
Cipher Pharmaceuticals Inc. (CPH.TO)
0.8$0.88-1.1%C$23.61 millionC$21.37 million3.11
Harvest One Cannabis logo
HVT
Harvest One Cannabis
0.4$0.15-3.3%C$21.51 millionC$8.50 million-0.42Gap Down
EVE
Eve & Co Incorporated
1.0$0.43-7.0%C$21.32 millionC$2.84 million-1.35Gap Up
SUGR
SugarBud Craft Growers Corp. (SUGR.V)
0.7$0.08-0.0%C$11.81 millionC$66,906.00-0.04News Coverage
NU
NeutriSci International
0.5$0.14-3.6%C$8.65 millionC$69,626.00-10.77Upcoming Earnings
Gap Down
AQS
Aequus Pharmaceuticals
0.9$0.23-0.0%C$6.03 millionC$2.28 million-10.23Gap Up
LBL
Lattice Biologics
0.5$0.05-10.0%C$4.67 millionC$2.46 million-3.57
THCX
(THCX.V)
0.6$5.30-6.2%C$0.00N/A0.00High Trading Volume
GLH
31444
0.4N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
ACG
438280
0.6N/AN/AC$0.00N/A0.00Gap Down
HC
815446
0.5N/AN/A$0.00N/A0.00Gap Down
BIO
Bio-Rad Laboratories
0.5N/AN/A$0.00N/A0.00High Trading Volume
BBM
Blueberries Medical
0.6N/AN/A$0.00N/A0.00High Trading Volume
LOVE
Cannara Biotech
0.7N/AN/A$0.00N/A0.00High Trading Volume
CALI
China Auto Logistics
1.3N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
MJ
ETFMG Alternative Harvest ETF
0.5N/AN/A$0.00N/A0.00Gap Down
BOSS
Global X Founder-Run Companies ETF
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
LHS
Liberty Health Sciences
0.5N/AN/A$0.00N/A0.00High Trading Volume
Gap Up
LIB
Liberty Leaf
0.5N/AN/AC$0.00N/A0.00High Trading Volume
Gap Down
MMEN
Medmen Enterprises
0.6N/AN/A$0.00N/A0.00High Trading Volume
RQB
Ravenquest Biomed
0.6N/AN/A$0.00N/A0.00High Trading Volume
TGIF
SoFi Weekly Income ETF
0.6N/AN/A$0.00N/A0.00High Trading Volume
Valeant Pharmaceuticals International logo
VRX
Valeant Pharmaceuticals International
0.5$30.80-3.4%C$0.00N/A0.00
VRT
Vertiv
0.5N/AN/A$0.00N/A0.00Gap Down
This page was last updated on 3/8/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.